The purpose of this study was to determine the prognostic value and oncogenic pathways associated to miRNA expression in squamous cell carcinoma of the oral tongue and to link these miRNA candidates with potential gene targets. We performed a miRNA screening within our institutional cohort (n 5 58 patients) and reported five prognostic targets including a cluster of four co-expressed miRNAs (miR-18a, miR-92a, miR-103, and miR-205). Multivariate analysis showed that expression of miR548b (p 5 0.007) and miR-18a (p 5 0.004, representative of co-expressed miRNAs) are independent prognostic markers for squamous cell carcinoma of the oral tongue. These findings were validated in The Cancer Genome Atlas (TCGA) cohort (n 5 131) for both miRNAs (miR-548b: p 5 0.027; miR-18a: p 5 0.001). Bioinformatics analysis identified PTEN and ACTN4 as direct targets of the four co-expressed miRNAs and miR-548b, respectively. Correlations between the five identified miRNAs and their respective targeted genes were validated in the two merged cohorts and were concordantly significant (miR-18a/ PTEN: p < 0.0001; miR-92a/PTEN: p 5 0.0008; miR-103/PTEN: p 5 0.008; miR-203/PTEN: p 5 0.019; miR-548b/ACTN4: p 5 0.009).
It is estimated that 30,260 individuals in the United States are diagnosed annually with oral cavity carcinoma. 1 The distinctive anatomy of the oral cavity, in close proximity to a dense lymphatic network and neurovascular structures, tends to cause rapid and aggressive local cancer invasion. 2 Squamous cell carcinoma is the most frequently observed histological subtype, reported in 90% of head and neck cancers, and affects most commonly the oral tongue. 3 Despite improvements in multimodality management, oral cavity carcinoma (OCC) has persistently shown poor therapy response and unfavorable overall survival outcomes within the first 5 years of follow-up. 4 The development of squamous cell carcinoma of the oral tongue (SCCOT) has been attributed to tobacco smoking and alcohol abuse, 5 while past reports failed to consistently show a clear contributive role of human papilloma virus (HPV). 6 nature of oral tongue carcinoma and have been suggested to be driven through specific mutations and gene expression modulated by epidemiologically distinctive patient characteristics. 9 Improved molecular understanding in gene expression patterns would thus play an important role in defining a better portrait of oral tongue carcinoma and to explore clinical correlations among various subgroups of patients. Post-transcriptional cancer regulatory processing through miRNA has been attributed to play an important role in gene expression and cancer regulation. 10 Advancement in microarray technologies has thus allowed improved characterization and screening of miRNAs and mRNAs expression within various tumor tissues. 11 Altered regulation of miRNAs through changes in functional activity induces variations in target protein expression. 12 The PI3K/Akt/mTOR signaling is frequently altered across multiple cancers. 13 Among the eight known PI3K kinase subclasses, the class I intracellular signaling has been acknowledge to play a role as an oncogenic driver in various cancers types, including solid tumors such as breast, pancreatic, and renal carcinoma. [14] [15] [16] The PI3K protein can be activated by several tyrosine kinases, enabling phosphorylation and production of PIP3, which serves as a downstream second messenger through Akt signaling activation. 17 The Akt pathway induces increased cell proliferation and survival. In addition, the mTOR kinase activity allowing protein synthesis and cell growth is also dependent from regulation of the PI3K/Akt signaling complex. 18 Therefore, the PI3K/Akt/mTOR axis is described as a whole, and has been the center component of emerging therapeutic anticancer agents. In a past clinical trial, authors demonstrated that patients which showed initial response to PI3Ka inhibition therapy eventually became refractory to additional treatment, but noted promising good response in cell line work using a combined therapy targeting Axl or EGFR (epithelial growth factor receptor) inhibition. 19 Also, a recent study reported favorable clinical outcomes for head and neck squamous cell carcinoma (HNSCC) using buparlisib, a specific oral-specific inhibitor of the pan-class I PI3K family. 20 Although dozens of miRNAs have been shown to regulate the PI3K/Akt/mTOR oncogenic signaling pathways, 21 the interaction between miRNA regulation and these pathways specifically in SCCOT remains not fully understood. Among several key protein targets in cancer regulation, the implication of the oncogenic receptor tyrosine kinase Axl protein has been of an increased interest in HNSCC. 22 Axl expression has been attributed in the development and progression of many cancers, including OCC, while increased levels appear associated to poor clinical outcomes. 19 Moreover, Axl is an inducer of the PI3K/Akt signaling pathway. 22 Axl expression has shown to mediate resistance to anti-EGFR therapy (cetuximab), which is considered a major molecular target in HNSCC. 23 Past studies have assessed miRNA expression in HNSCC as a whole, although none has previously specifically evaluated SCCOT through the assessment of two large independent cohorts for an unbiased miRNA expression analysis. To improve our understanding of miRNA regulation in SCCOT population, the purpose of this study aimed to identify specific miRNA expression and to assess its potential prognostic value. In addition, we explored the main oncogenic pathways associated to the previously identified miRNAs. We hope that these novel prognostic tools and their relationship with gene expression will facilitate a better understanding of the disease on a molecular level and contribute to a potential emergence of individualized targeted therapy.
Material and Methods

Patients and specimens
A total of 58 patients were recruited at the "Centre Hospitalier de l'Universit e de Montr eal" (CHUM) and have undergone surgical resection for primary SCCOT between 2010 and 2015. All patients provided informed consent to participate to our head and neck tumor biobank, member of the Canadian Tissue Repository Network. Patient information was prospectively collected through the "Système d'Archivage des Donn ees en Oncologie" cancer registry. Clinical parameters, including patient demographics, past medical history, tobacco exposure, and alcohol, were recorded. In addition, oncological and pathological parameters, including TNM staging and nonsurgical therapy modalities details, were also obtained from medical records ( Table 1) .
The Cancer Genome Atlas (TCGA) is a publically available data repository in the form of large-scale genome sequencing database generated by the TCGA Research Network (http://cancergenome.nih.gov/). 24, 25 All 131 patients from the TCGA SCCOT were evaluated as an independent cohort from the CHUM cohort. HPV positivity was assessed by P16 immunofluorescence for the CHUM cohort and both by P16 immunochemistry and in situ hybridization for the TCGA cohort. Paraffin-embedded formalin-fixed samples were processed by the CHUM pathology department. Tumor and normal tissue were reviewed by trained head and neck pathologists (J.
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Guilmette and O. Gologan). All experiments of this study were conducted without prior knowledge of the patient survival. This study was approved by our Institutional Ethics Review Committee.
RNA extraction
Identification of the tumor and healthy tissue was performed on a hematoxylin and eosin stain for all 58 patients. On a second slice of 10 mM, nonspecific tissue was scrapped with a scalpel to conserve only the tumor or healthy section, which was transferred in a clean tube. RNA extraction was performed using RecoverAll Total Nucleic Acid Isolation Kit for FFPE (Thermo Fisher Scientific) according to the manufacturer's recommendations. RNA quantification was done using the 260 nm absorbance with a NanoDrop ND-1000 spectrophotometer.
MiRNA quantification
All 58 tumor samples and the 36 matched control tissues with the highest RNA yield were used for the miRNA quantification step. A range of 11.3-15.0 mg and 2.8-15.0 mg was used for tumor and healthy tissue, respectively, to perform reverse transcription using TaqMan MicroRNA Reverse Transcription Kit (Thermo Fisher Scientific). The 8 mL reaction mix contained 13 Megaplex RT Primers Human Pool A v2.1 (Thermo Fisher Scientific), 13 RT buffer, 2.5 mM dNTPs, 75 lL MultiScribe RT enzyme, and 2 lL RNase inhibitor. Reverse transcription conditions included 40 cycles of 168C for 2 min, 428C for 1 min, and 508C for 1 min. Reaction was terminated by a 5 min incubation at 858C.
Preamplification was performed using a mix of 2 mL cDNA, 2.5 mL TaqMan PreAmp Master Mix 23 (Thermo Fisher Scientific) and 0.5 mL MegaPlex PreAmp Primers Human Pool A v2.1 (Thermo Fisher Scientific). Preamplification conditions included a 10 min period at 958C, 2 min at 558C, and 2 min at 728C, followed by 14 cycles of 958C for 15 sec, and 608C for 4 min. Reaction was terminated by a 10 min incubation at 99.98C.
Real-time PCR analysis was performed using four Fluidigm 96.96 integrated fluidic circuits on the Biomark HD system (Fluidigm). TaqMan Universal Master Mix II, no UNG (Thermo Fisher Scientific) was used according to the manufacturer's recommendations with 377 different miRNA TaqMan assays (Thermo Fisher Scientific, Supporting Information, Table S1 ). U6 and RNU48 were used as controls and were measured on the four integrated fluidic circuits.
Immunofluorescence
Formalin-fixed paraffin-embedded (FFPE) samples were collected from our institutional cohort. A tissue microarray including two punches of each tumor tissue was assembled, and immunofluorescence staining was performed as previously described. 26 Assessment of p16 status (presence or absence) (Santa Cruz Biotechnologies, JC8, 1/500 dilution), Axl (R&D Systems, AF154, 1/100 dilution), PTEN (Spring Bioscience, SP218, 1/50 dilution), and ACTN4 (SigmaAldrich, HPA001873, 1/70 dilution) were performed in combination to the analysis of cytokeratin H.M.W. (Cedarlane, 34bE12, 1/500 dilution). The cytokeratin staining was used to determine the areas composed of epithelial cancer cells as previously described. 26 The mean detected fluorescence intensities of Axl, PTEN, and ACTN4 were measured using the VisiomorphDP platform. A mean value of the two tumor cores for each patient was used for the analysis.
Statistical analysis
Gene expression and protein data were normalized using z scores for statistical analysis. For cohort characteristics comparison, Pearson's Chi-squared test was used to compare nominal variables and t test for continuous numerical variables. Upregulation of miRNA in the tumor tissue was analyzed using a paired sample t test and Cohen's d effect size, pairing healthy and tumor tissues within the same patient. A likelihood ratio test was used to evaluate hazard ratios and to perform the multivariate prediction model. Kaplan-Meier curves were assessed using log-rank p values, hazard ratios, and confidence intervals (CI) of the high-level group. Multivariate correlations between miRNAs expression were analyzed using Pearson correlation coefficient p and r values. A robust regression model using Huber M-estimation was used for evaluation of miRNA and target gene univariate correlations to prevent false positive due to aberrant outliers. Differences in miRNA expression between clinical groups were tested using the Wilcoxon signed-rank test. Throughout the analyses, p values <0.05 were considered statistically significant. Statistical analysis was performed using JMP 12.0.1 statistical software (SAS Institute Inc.).
RESULTS
Descriptive data of the SCCOT CHUM and TCGA cohorts Demographic and clinical parameters of patients in the CHUM and TCGA cohorts are available in Table 1 . A positive alcohol status included patients with current or prior alcohol use in the CHUM cohort. Patients with documented consumption of 1 drink/day were considered positive in the TCGA cohort. Alcohol use history, tumor size, and node status differed significantly between the two cohorts. All other clinical parameters did not significantly vary between both groups. Importantly, follow-up time and overall survival were similar in the two cohorts. Unknown data were not taken into account for this analysis.
Selection of candidate prognostic miRNAs from a 375 miRNA screen
To select candidate prognostic miRNAs, we profiled the miRNA expression from the CHUM cohort instead of the TCGA data, as our group of patients had no missing data and all samples were collected from the same institution, thus reducing potential variations in sample collection. Also, our group of patients included a much greater number of paired healthy tissues than the TCGA cohort.
We predefined a strategy to identify candidate prognostic miRNAs that tested: (1) detectable levels in at least 80% of the samples for reliable statistical analysis; (2) ROC area under the curve (AUC) 0.65 according to patient alive/ deceased status at 7 years or at the end of follow-up, as an initial screening tool; (3) upregulations in tumor tissue in comparison to paired healthy tissue to confirm specific tumor miRNA expression; and (4) statistically significant hazard ratios for both studied cohorts using two equally distributed n 5 29 low and high expression groups, as a second unbiased screening tool of predictive value (Table 2) .
A total of 375 miRNAs were screened within the CHUM cohort, including 58 tumor samples and 36 matched control tissues. The 2
Dct miRNA values were normalized according to the average of U6 and RNU48 ct values. Eighty-six miRNAs were detected in at least 80% of tumor samples in the CHUM cohort (Supporting Information, Table S2 ). Eight miRNAs had ROC AUC 0.65 (miR-92a, miR-18a, miR-103, miR-205, miR-548b, miR-532, miR-20a, and miR-365; Supporting Information, Fig. S1 ). All eight miRNAs were upregulated in tumor tissue in comparison to their matched normal tissues ( Supporting Information, Fig. S2 ). Only miR-92a, miR-548b, miR-18a, miR-103, and miR-205 had significant unbiased hazard ratios and were therefore selected as potential prognostic miRNAs. 
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Univariate analysis of the selected five potential prognostic miRNAs
Following the initial identification of candidate miRNAs, we assessed the prognostic significance of these targets within the CHUM and TCGA cohort. In addition, we also evaluated the reproducibility of our results in concordance to a previously known prognostic factor, Axl, which has been demonstrated to have a strong prognostic value. Increased Axl levels were associated with poor outcomes in SCCOT and head and neck carcinoma in two independent past studies (p < 0.0001, HR 5 2.0 and p 5 0.007, HR 5 1.7). 22, 27 Association between expression of miR-92a, miR-548b, miR-18a, miR-103, and miR-205 and patient prognosis was tested in the CHUM and TCGA cohort (Figs. 1a-e) . Patients were classified according to miRNA expression levels (high or low) using the threshold maximizing the prediction value Figure 1 . Five miRNAs and Axl protein/RNA expression levels are prognostic for patient survival in SCCOT patients. Comparison of patient survival for all SCCOT patients of the CHUM and TCGA cohorts using the Kaplan-Meier curve estimation and log-rank test univariate survival analysis for tumor high (black) and low (gray) levels of (a) miR-92a, (b) miR-18a, (c) miR-103, (d) miR-205, (e) miR-548b, and (f) Axl. (g) Representative high and low Axl immunofluorescence stainings. The three patients from the TCGA cohort with no Axl expression data were removed from the analysis (f). Protein levels were used for Axl assessment in the CHUM cohort. Other analysis used miRNA and mRNA levels. p values were calculated using the log-rank test. [Color figure can be viewed at wileyonlinelibrary.com] on a ROC curve associated to patient alive-deceased status (sensibility 2 (1 2 specificity)). ROC curves and their respective cutoffs are shown on Supporting Information, Figure S1 . A seven-year follow-up interval was used in both cohorts according to the longest recorded time assessment in the CHUM group.
Axl protein levels were measured using immunofluorescence in the CHUM cohort (Supporting Information, Table S3 ), in addition to expression level available in the TCGA cohort. These results were included in the multivariate likelihood ratio test. In addition, the prognostic value of AXL was evaluated in both cohorts (Fig. 1f) . Representative Axl immunofluorescence stainings are shown in Figure 1g . Assessment of Axl expression level was included in our multivariate model to determine the prognostic significance of the previously identified miRNAs in association to the known prognostic value of Axl expression.
Significant expression differences were observed for the five miRNAs and Axl in the CHUM cohort, while only for miR-18a in the TCGA cohort with nonsignificant trends observed for the other candidates. We hypothesized that a multivariate analysis including clinical parameters would thus help confirm the prognostic value of the five identified miRNAs and Axl in the TCGA cohort.
Four miRNAs are co-expressed and inversely correlated with PTEN, while miR-548b is independently expressed and inversely correlated with ACTN4
To conduct a multivariate analysis, we assessed any potential redundancy results of our five candidate miRNAs, using a correlation analysis. Our findings demonstrated that miR92a, miR-103, miR-18a, and miR-205 are strongly correlated together, in both cohorts (Table 3) . These findings appear to suggest an underlying co-expression process, for which the miRNAs prognostic value may be redundant. Multivariate analysis revealed strong correlations (p < 0.0001; r ranging from 0.35 to 0.91) between miR-92a, miR-18a, miR-103, and miR-205 in both cohorts, at the exception for miR-103 and miR-205 in the TCGA cohorts (p 5 0.064), while no significant association was noted for miR-548b and the other candidates. Also verified was the relationship between clinical parameters (tumor size, node status, gender, age, HPV, smoking, and alcohol history) and miRNA expression (Supporting Information, Table S4 ). Albeit expression of the four co-expressed miRNA is higher for patients with smoking history (p values from 0.006 to 0.077) in the CHUM cohort, this effect was not reproduced in the TCGA cohort. Also, expression of miR-18a was significantly lower (p 5 0.048) for Table S5 ). We then cross-referenced the 5 miRNAs' validated targets with the Axl activated PI3K/Akt pathway and observed two targets; miR-548b associated to ACTN4 and the four coexpressed miRNAs targeting PTEN (Fig. 2a) .
In silico data were verified within our studied groups. As RNAs/miRNAs were extracted from FFPE tissues, their quality (RIN 1.00-2.40) was insufficient to directly quantify the expression of potential target mRNA, which were fragmented when compared to short miRNAs in FFPE samples. 30 We therefore used the same tissue microarray as for Axl and p16 analysis to evaluate PTEN and ACTN4 levels in tumor tissues (Supporting Information, Table S3 ). Representative high and low PTEN and ACTN4 immunofluorescence stainings are shown in Figures 2b and 2c . Previously identified miRNA levels were used in the TCGA cohort. Data for both cohorts were normalized using z scores to test for correlation pooling both cohorts. z score normalization of the miRNA expressions was performed to confirm the inverse correlation of PTEN with miR-18a (p < 0.0001, Fig. 2d ), miR-92a (p 5 0.0008, Fig. 2e ), miR-103 (p 5 0.008, Fig. 2f) , and miR-205 (p 5 0.019, Fig. 2g ). An inverse correlation between ACTN4 with miR-548b (p 5 0.009, Fig. 2h ) was also confirmed. Correlation analysis between miRNA expression and their target gene was assessed separately in both cohorts. In the CHUM cohort, inverse correlations were significant for miR-205/PTEN (p 5 0.003), miR-18a/PTEN (p 5 0.005), and miR-92a/PTEN (p 5 0.021). Concordantly, in the TCGA cohort inverse correlations were also significant for miR548b/ACTN4 (p < 0.0001), miR-18a/PTEN (p 5 0.0005), miR-92a/PTEN (p 5 0.016), and miR-103/PTEN (p 5 0.032) (Supporting Information, Table S6 ).
Axl, miR-548b, and miR-18a are independent prognostic factors
To proceed to a multivariate likelihood ratio test assessing overall survival outcomes on the same seven-year time period as for the univariate analysis, we subdivided our groups using standardized TNM tumor size (pT), nodal status (pN), and smoking status, thus comparing small (T2, 4.0 cm) and large (T3, >4.0 cm) tumors, negative lymph (N0) and positive lymph node status (N1), never smokers and reformed/ current smoking patients, respectively. Age noted at the initial diagnosis aimed to compare younger (50 years) and older (>50 years) patients. HPV status and past history of alcohol use were also assessed in the CHUM analysis, but removed from the TCGA analysis due to a high number of missing data causing too much bias in the multivariate analysis. Those clinical parameters were also tested with a univariate analysis with no significant results in the CHUM cohort and smoking history being the only significant factor (p 5 0.034; HR 5 2.00, CI 5 1.07-4.01) in the TCGA cohort ( Supporting Information, Fig. S3 ). As miR-18a, miR-92a, miR-103, and miR-205 were co-expressed, only miR-18a was included in the multivariate analysis as it had the most significant univariate prognostic value in both cohorts. Axl was also included in our model to assess the role of the candidate miRNAs as Axl-independent prognostic factors. Three factors appeared significantly correlated to overall survival in both cohorts; miR-548b, Axl, and miR-18a expression (Table 4 ). In addition, nodal status was also significant but only in the CHUM cohort.
The same analysis was also performed looking at progression-free survival with miR-18a being the only significant factor in both cohorts (Table 4) . We also performed the same multivariate analysis for overall and progression-free survival while removing the Axl parameter (Supporting Information, Table S7 ). The same parameters remained significant in the CHUM cohort while for the TCGA cohort miR-548b lost significance for overall survival (p 5 0.070) and age for progression-free survival (p 5 0.34).
DISCUSSION
To assess the regulatory function of miRNAs in SCCOT, we performed a large miRNA screening, and determined the clinical value of miRNAs expression in our institutional group of patients. Our results suggest that the expression levels of miR92a, miR-18a, miR-103, miR-205, and miR-548b can be useful prognostic tools. Past reports have also evaluated the role miRNAs in HNSCC and in other cancers sites. Zhang et al. have shown that miR-92a expression was an unfavorable prognostic marker 31 for nasopharyngeal carcinoma, while the coexpression of miR-18a and miR-92 as part of the miR-17/92 cluster, also known as oncomiR-1, 32 was associated to worst prognostic outcomes in esophageal squamous cell carcinoma. 33 Among other identified miRNAs, previous studies also reported that miR-103 is an unfavorable prognostic factor for breast and colorectal cancer, 34, 35 while miR-103 appears as a poor prognostic marker in endometrial and early stage nonsmall-cell lung cancer. 36 In addition, expression of miR-548b was noted to be an important indicator of good prognostic outcomes for Axl-driven non-small-cell lung cancer. 37 Although we noted differences in data significance between the CHUM and TCGA cohorts using the univariate analysis, these findings may be explained by distinctive cohort characteristics, such as tumor stage and pathological grade. These differences would thus be explained by initially different tumor tissues collected in the TCGA and CHUM group. It should be noted that the TCGA dataset required larger tumor samples (1 cm) in comparison to the CHUM biobank samples (0.5 cm), suggesting that tumors with higher staging and pathological grade were preferentially collected in the TCGA group. This could also explain why optimized thresholds found using ROC curves for survival analysis in the TCGA cohort had a larger percentage of patients in the high group for the deleterious miRNAs and in the low group for the protective miR-548b.
Multivariate analysis was used to confirm the predictive value of the identified candidate miRNAs in both cohorts.
Correlations between miR-92a, miR-103, miR-18a, and miR-205 are very strong with quite high r values for in vivo correlations (Table 3) . MiR-18a and miR-92a are expected to be correlated as they are encoded in the same RNA transcript Tumor Markers and Signatures cluster. 32 Therefore, having r values in the same range (and sometimes higher) for all six correlations suggests a strong common control mechanism. For this reason, we used only one of the four co-expressed miRNA for the multivariate analysis as we would not be able to distinguish the single miRNAs effects in this study. The miR-18a was the only candidate among the four co-expressed miRNAs which was used in the multivariate survival analysis, as it had the most significant prognostic value in both cohorts, and allowed to avoid redundancy with the exclusion the three other candidates (miR-92a, miR-103, and miR-203). In addition, expression of Axl and miR-548 were included as distinctive risk factors. They appeared as independent prognostic factors, which is logical as they are independent regulatory effectors on the PI3K-Akt pathway (Fig. 2a) . The independent prognostic value of those miRNAs was consistently reproducible in the CHUM and TCGA group, although the two cohorts had significantly different clinical tumor characteristics, suggesting their prognostic value is relevant during the complete development of the disease. Higher hazards ratios are observed in the CHUM cohort in comparison to the TCGA cohort. This is explained by the fact we used our in house cohort for selection of candidate prognostic factors with a stringent screening strategy, hereby ending up with highly significant results. Also, smaller cohorts may lead to broader confidence intervals which are observed in our cohort. This is why the TCGA cohort is so important in this study as larger confirmation cohort and also because it was not used for the selection of the candidate prognostic miRNAs and therefore analysis of those miRNAs in that cohort was unbiased. With this in mind, it is impressive that the miR-18a prognostic value stays highly significant (p 0,004) in both cohorts for both overall and progressionfree survival, suggesting that the four correlating miRNA (miR-18a, miR-92a, miR-103, and miR-203) are quite important in SCCOT. Interestingly, removing Axl from the multivariate analysis caused a loss of significance for miR-548b in the TCGA cohort, but not in the CHUM cohort. Also, miR548b was not significantly predictive of progression-free survival in both cohorts and its multivariate p values were always lower than those of miR-18a and Axl in both cohorts and for both overall and progression-free survival. This suggests that miR-548b effect might be less important than those of miR-18a or Axl. An inverse correlation between PTEN expression and miR-18a, miR-92a, miR-103, and miR-205 was predicted in silico and confirmed in the SCCOT cohorts. The four coexpressed miRNAs appear all very strongly correlated together, show significant inverse correlations with PTEN regulation, and appear to have an interesting predictive value in our multivariate model. PTEN is a known prognostic factor in SCCOT, which interestingly appears to be a common target for the co-expressed miRNAs. 38 These co-expressed miRNAs seem to have a global prognostic effect, not only through expressing of miR-18a, as observed in the multivariate model, but more as effectors to a common target. PTEN is an important tumor suppressor which downregulates the PI3K/Akt pathway by catalyzing dephosphorylation of PIP3. 39 Although PTEN mutations have been often reported in other cancers subtypes, it appears rarely affected in head and neck carcinomas, 40 therefore suggesting a logical anticancer target for miRNAs. PTEN regulation through expression of miR-92a has been demonstrated in nasopharyngeal carcinoma and linked to a poor overall survival and disease-free survival. 31 In addition, downregulation of PTEN in association to miR-103, miR-18a, and miR-205 regulation has also been established in other tissues, including the nasopharynx. [41] [42] [43] [44] [45] An inverse correlation between ACTN4 expression and miR-548b was predicted in silico and confirmed in the SCCOT cohorts. Our results suggest that miR-548b expression appears to be a protective prognostic marker, which has seldom been previously reported in cancer studies. ACTN4 is considered an important PIP3-dependant regulator of Akt, which binds Akt and translocates with it as a complex to the nuclear membrane and specific silencing of ACTN using siRNA is shown to reduce Akt phosphorylation and activity. 46 In a past study using oral squamous cell carcinoma cell lines, ACTN4 silencing has also been attributed to reduce cancer invasion potential. 47 Nevertheless, specific regulatory mechanism by which this process promotes patient survival requires further investigations. It should also be stated that other relevant targets independent of the PI3K-Akt axis may exist, and would thus have interesting prognostic value in association to miRNAs expression. In this study, we note that the three reported independent predictive factors (the miR-18a/miR-92a/mir-103/miR-203 signature, miR-548b, and Axl) appear to show an interesting common association to the PI3K-Akt axis. Specific targeting of the PI3K axis has been recently reported to promising clinical outcomes. 19, 20 Three FDA approved therapeutic agents for HNSCC are currently available, including cetuximab, targeting EGFR, through an upstream regulatory effect on the PI3K-Akt axis, 48 and anti-PD-1 immune checkpoint inhibitors pembrolizumab and nivolumab, which inhibit immune invasion by blocking the interaction between T-cell PD-1 and tumor cell PD-L1. 49 Ritprajak et al. have previously shown that PI3K promotes PD-L1 expression in mouse HNSCC and in human oral squamous cell carcinoma. 50 We suggest that modulation of miR-548b, miR-18a, miR-92a, miR-103, and/or miR-203 expression level may confer additional therapeutic benefits through indirect regulation of the PI3K axis.
In summary, this work used two independent cohorts to discover and validate two novel prognostic tools for SCCOT, including the ACTN4 inversely correlated miR-548b and the PTEN inversely correlated miRNA cluster group consisting of miR-18a, miR-92a, miR-103, and miR-203.
